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ABSTRACT: One of the main targets in current clinical oncology is the development of a cheap device 
capable of monitoring in real-time the concentration of a drug in the blood of a patient. This would 
allow fine-tuning the dosage according to the patient's metabolism, a key condition to reduce side 
effects. By using surface plasmon resonance and fluorescence spectroscopy we here show that short 
peptides designed in silico by a recently developed algorithm   are capable of binding the anticancer 
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drug irinotecan (CPT-11) with micromolar affinity. Importantly, the recognition takes place in the 
denaturating solution used in standard therapeutic drug monitoring to detach the drug from the proteins 
that are present in human plasma, and some of the peptides are capable of distinguishing CPT-11 from 
its  metabolite SN-38. These results suggest that the in silico design of small artificial peptides is now a 
viable route for designing sensing units,  opening a wide range of applications in  diagnostic and clinical 
areas. 
Keywords: peptides; drug monitoring; in silico design; irinotecan. 
 
1. Introduction 
An optimal therapeutic protocol for cancer should ensure the best response with minimal toxicity. 
However, achieving this goal is far from simple, since several factors may affect the drug concentration 
in the blood of a patient  under treatment. These include, among the others, the gender, the age, the  
health status and  pharmacogenomics variations in genes encoding enzymes involved in drug absorption 
and metabolism (Ma and Lu 2011). Therapeutic Drug Monitoring (TDM) aims at measuring directly the 
concentration of the drug in the blood of the patient. This allows, at least in principle,  personalizing the 
treatment by adjusting the dosage and reducing side effects (Walko and McLeod 2014; De Jong et al. 
2005; Alnaim 2007). It is particularly useful for monitoring drugs employed in long-term treatments or 
drugs that have a narrow therapeutic range. Drugs suitable for TDM are characterized by a known dose-
dependent response, a significant inter-individual pharmacokinetic variability, a narrow therapeutic 
window  exposure-response relationship, and  anticancer drugs meet these criteria (Paci et al. 2014).  
TDM involves measuring drug concentrations in plasma, serum or blood at designed time intervals, 
ideally in continuum. In the clinical care it is a routine practice only for few drugs. It represents a 
valuable guidance for antibiotics, immunosuppressives, antiepileptics, while for anticancer drugs is still 
uncommon (Gao et al. 2012; Widmer et al. 2014).  Currently, the main technologies applied in the TDM 
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of anticancer drugs are based on the  extraction of the drug from blood or plasma samples, followed by 
HPLC or LC-MS (Marangon et al. 2014; Van Erp et al 2014) analysis. However, the HPLC 
instrumentation is expensive and generally available only to laboratories of hospitals and research 
centers. Developing a point of care device, that can be used directly at the patient bed or by the patient, 
with simple sample preparation, high robustness, sensitivity and good selectivity is still an open 
technological challenge. Such a device should ideally be based on a biosensor equipped with a stable 
and cheap sensing elements. A possible option is using an aptamer changing its conformation upon 
binding, as  reported and tested on animal models (Ferguson et al. 2014).  
Short peptides offer a viable alternative to aptamers for designing sensing elements for TDM, since they 
can be easily synthesized in large quantities, are cost-effective and bio-stable. Despite of these 
potentialities, their use in real-world application is still rather limited. Indeed, short peptides cannot be 
designed by exploiting a natural selection mechanism, like is done for antibodies. Designing the 
peptides in silico is also highly non trivial, due to their high flexibility and the large conformational 
changes which can be triggered by a single mutation. A further difficulty arises in the specific field of 
TDM: protein precipitation, the most common sample preparation procedure, in TDM is performed by 
adding to the patient sample a significant fraction of denaturant in order to detach the drug from the 
proteins to which it is bound (typically albumin). Since the binding affinity can change significantly in a 
denaturizing environment, the design cannot be carried on using as templates peptide fragments binding 
the target in water solutions.  
In order to overcome the above-mentioned difficulties, we have recently developed a computational 
protocol providing a route to design short peptides with high affinity and selectivity for organic 
molecules in a solvent specific environment (Gladich et al. 2015).  In short, the approach is based on a 
stochastic search in the peptide sequence space driven by a series of single point mutations. At each 
mutation step, a conformational sampling is performed by molecular dynamics simulation in explicit 
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solvent environment and  the mutation is accepted or rejected according to a Monte Carlo scheme 
targeted at improving the estimated stability of the complex. Modeling the solvent explicitly allows 
taking into account the non-trivial effect of the denaturant on the strength of the contacts stabilizing the 
drug-peptide complex. Recently, this computational scheme allowed the design of peptides capable to 
recognize chlorogenic acid by electrochemical detection in food samples (Del Carlo et al. 2016).  
In this paper we analyzed theoretically and experimentally the peptides designed by the above 
computational approach and we  give the prove of their  capability to bind CPT-11 (Scheme 1) in a 
denaturant solution, namely in the conditions commonly used for TDM, showing evidence that short 
peptides designed in silico can be used as sensing elements for TDM of anticancer drugs. These 
peptides are, indeed, by construction solvent specific, i. e., capable to recognize the target in the solvent 
in which they have been designed. This calls for applications in devices in which the peptide-based 
sensor is required to work in denaturants or under extreme conditions of pH and/or salt concentration. 
 
Scheme 1 
2. Materials and methods 
Design of peptide sequences: we used the procedure previously developed and described in detail in 
Gladich et al. 2011 in order to design short cyclic peptides with high binding affinity toward CPT-11. 
The search of the optimal sequence starts considering the target molecule inserted in a cyclic peptide of 
12 VAL closed at the end by a disulfide bridge between two cysteines. We then randomly selected one 
amino acid from the peptide and replaced it with a different one, while the two terminal cysteines 
connected with a disulfide bridge are excluded  to preserve the cyclic geometry of the peptide. In this 
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way, the new peptide sequence at the step i+1, SEQi+1, differs from the sequence at the previous step, 
SEQi, for only one amino acid at the time. The stability of the complex after each mutation step were 
estimated by the mean value Ei of Vina21 (Trott et al. 2010) scoring function calculated on the 
molecular dynamics (MD) trajectory. The new peptide sequence SEQi+1 is accepted or rejected 
according to the Metropolis criterion, with a probability min(1, exp[(Ei+1 − Ei)/Te]) controlling the 
acceptance rate by an efficacious temperature, Te. In the case of acceptance, a new mutation is 
attempted on the new structure, otherwise on the previous one. The mutation cycle was iterated until the 
estimated binding affinity reached a plateau (see Figure 1). In order to enhance the exploration of the 
sequence space, five simultaneous and independent mutation cycles at five efficacious temperatures Te 
= 0.2, 0.4, 0.6, 0.8, and 1.0 kcal/mol were performed, attempting to swap two replicas, r and r´, at the 
end of each mutation step. A swap between the states of replica r at Tr, (SEQr, Er) and the state of 
replica r´ at Tr´, (SEQr´, Er´) was accepted with probability min(1, exp[(Er − Er´)(1/Tr − 1/Tr´)]).  
This mutation cycle was iterated until the estimated binding affinity reached a plateau, visible in Figure 
1. A set of different peptide sequences was selected from the outcome of the design cycle among those 
with higher binding affinity and with, at least, three amino acid difference in the sequences. In 
supplementary data we report an example of the design output with a table of the first 60 peptides with 
higher affinity toward CPT-11 in MeOH. Within this set we further selected between 5 to 10 sequences 
for a theoretical validation of their thermal stability, performing long MD trajectories at 300 K. To test 
the stability of the complex we can choose the same setup used in the design, or a different environment. 
For example, we can change the solvent. In the present work the peptides 1-3 were designed in vacuum 
and tested in water and methanol on a 200 ns NPT simulations at 300 K. Peptides 4-5 were designed 
specifically in methanol and tested in water and methanol. Peptides 1-5 in Table 1 were chosen for 
experimental validation among those that showed higher thermal stability and affinity over the course of 
200 ns MD. 
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                                                  a                                                                      b 
Figure 1 
 The MD runs were performed using GROMACS molecular packages (Hess et al. 2008). At each 
mutation step, we performed 500000 steps of steepest descent energy minimization in explicit solvent, 
followed by 50 ps   NVT equilibration  and afterwards by 5 ns constant temperature and pressure (NPT) 
run. During the NVT and NPT runs the temperature was kept at 300 K. The peptide and solvent 
molecules were modelled by the  AMBER99SB  force field (Hornak et al. 2006), while GAFF force 
field was used for CPT-11. The  two metabolites CPT-11 and SN-38 that we  considered in this work 
are stable at pH=4.5 and in this condition they are active as anticancer drugs. In the 4.5-7 pH range, 
among the tetratable residues (Lys, Arg, Asp, Glu, His), only His can change the protonation state. 
Moreover, the effect of the pH on the protonation state of His in methanol is known only qualitatively.  
We therefore performed the design considering the neutral form of His. For a few selected 
configurations and sequences, we then computed the binding affinity using a protonated His; the 
difference on the VINA binding affinity is typically of the order of 1 kcal/mol, significantly smaller than 
the statistical error. Therefore, in this specific case the effect of the change of the protonation of the 
amino acids can be neglected. Similarly, we did not take into account the effect on the binding affinity 
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of the ionic strength, as our aim was to obtain peptides capable to bind their targets in an organic 
environment.  
Design for experiments: to carry on some of  the  experiments it is necessary to immobilize the peptides 
on a surface,  for example on the SPR chip. To this aim we added a short additional chain of amino 
acids at the amino terminus of the designed peptides, to act as a linker between the cyclic peptide and 
the surface.  We have chosen for the linker the sequence LysGlyGlyGly and on a few cases we tested 
via molecular dynamic simulation that this linker do not affect the ligand-peptide binding affinity.  
Furthermore with molecular dynamic simulation we analyzed the effect of the presence of a surface on 
the structure of the complex:  we modeled a SiO2, using the  parameters as defined in the   DREIDING 
force field. During the NVT dynamics (T = 300 K) kept the terminal amino group of Lys at a distance of 
3.5 A from the surface. During the simulation the CPT11-peptide complex remains far from the surface, 
and we did not observe significant changes in the ligand-receptor interactions.  
Consistently with these theoretical results, we will show in the following that the binding 
affinity  estimated by SPR and by florescence spectroscopy is very similar. 
Surface Plasmon Resonance: the binding affinity was evaluated by Surface Plasmon Resonance using 
a BIAcore X100 instrument (GE Healthcare Europe GmbH). The peptides were immobilized on the 
CM5 sensor chip using a standard amine coupling in 10 mM sodium acetate buffer (pH 4.5). As a 
reference surface,  “flow cell 1” was treated with ethanolamine.  
The binding was revealed by increasing CPT-11 concentrations in continuous flow; eight different 
concentrations of CPT-11  (from 0.5 µM to 200 µM) were injected over each surface using 10 mM 
sodium acetate buffer pH 4.5 as running buffer and a flow rate of 30 µl/min for 180 sec. The 
dissociation step was performed using the same buffer and the same flow rate for 300 sec. Non-specific 
binding was eliminated subtracting the signal obtained from the reference flow cell. The final binding 
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sensorgrams were analysed using the BIAevaluation software  and by fitting the curves using the Steady 
State Affinity model.  
Fluorescence spectroscopy: fluorescence spectra were recorded on a CARY Eclipse (Varian) 
spectrofluorimeter at 25 °C. Concentrated mother solutions of  peptides 1-3 were prepared in water, 
while peptides 4 and 5 were dissolved in methanol. The concentration of  CPT-11 was fixed at 1 or 0.5 
µM in 400 µL of MeOH. Peptide concentration was increased from 1 nM to 100 µM adding 2 µL of the 
mother solutions for each concentration. The measurements were carried out in a 5 mm optical path cell. 
The excitation and emission wavelengths were respectively set at 220-430 nm or 267-425 nm in water 
and MeOH. The excitation and emission slits were set at 5 and 10 nm respectively. All the experiments 
were repeated three times. 
The quenching data obtained from the titrations were analysed according to the Stern-Volmer equation: 
F0/F= 1+Kq τ0[Q]=1+Ksv[Q]                                                                                                         
Where  F0 and F are the emission intensities before and after the addition of the quencher, respectively, 
Kq is the bimolecular quenching kinetic constant, τ0 is the fluorescence decay time of the fluorophore 
(about 3.5 ns for CPT-11,) (Dey et al. 1997), Ksv is the Stern-Volmer quenching constant and [Q] is the 
quencher concentration (peptide) in mol/L. At 1 µM CPT-11, the Stern-Volmer plots were linear in a 0-
100 µM quencher peptides range, and the Ksv values were determined by linear regressions; this allowed 
to estimate Kq (as Ksv/τ0). The dissociation constant of the CPT-11-peptides complexes and the 
stoichiometry of their formation were then evaluated by a Hill analysis: 
log (Θ/1-Θ)= n log [Q] – log KD   
where Θ was calculated as 1-F/F0 and represents the fraction of free binding sites, [Q] is the quencher 
concentration in mol/L, n is the number of binding sites, and KD is the dissociation constant. 
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3. Results and discussion 
We designed 16-residue long peptides following the procedure described in Gladich et al. 2015.  In 
order to reduce the entropic penalty in the unbound state, we designed cyclic peptides (Hong et al. 2012)  
keeping a disulfide bridge between the first and the last cysteine residues of the ring. Additional details 
on the computational procedure are reported in the Materials and methods section. In order to 
demonstrate the advantage of performing the design in explicit solvent, we (a) first considered peptides 
designed in vacuum with no explicit solvent and setting a simple cut-off on the non-bonded interaction 
and then (b) peptides designed in methanol, one of the solvent used in TDM to detach the drug from the 
protein. 
 
   Binding affinity for peptides designed in vacuum 
The binding affinity in water solution of the three cyclic peptides designed in vacuo (Table 1) was first 
estimated experimentally by Surface Plasmon Resonance (SPR), then by fluorescence spectroscopy. 
SPR was our method of choice to obtain rapid and accurate determinations of the binding affinity in 
water environment. The peptides were immobilized on the sensor chip surface, and their N-termini were  
linked to the carboxylic groups of the dextran matrix on the sensor chip by standard amine coupling. 
After immobilization, CPT-11 was injected in continuous flow over the sensor surface at increasing 
concentrations. Binding analyses were performed in acidic running buffer (10 mM sodium acetate, pH 
4.5) to protect the lactone ring of CPT-11 from opening, which occurs at neutral/basic pH (Fassberg et 
al. 1992). The experimental sensorgrams (Figure 2A) indicate that all three peptides have a good 
binding capacity towards CPT-11, showing  the response units (RU) of binding curves in the 
sensorgrams increasing with CPT-11 concentration. Decreasing the  concentration of the analyte down 
to 50 nM, the peptide maintains a detectable binding capacity, and the sensor gives a clean and 
reproducible signal. 
10 
 
For all the three  peptides, the association and dissociation kinetics of the peptide-CPT-11 complexes 
are very fast (see Table 1). This does not allow obtaining binding parameters from a kinetic analysis of 
the SPR data. However, using the steady-state values of RU, it was possible to calculate the dissociation 
constants (KD) from equibrium data with the BIAevaluation software.  The affinity turned out to be 64 
µM for peptide 1 (Table 1). Similar values of 63 and 62 µM  were obtained for peptides 2 and 3 
respectively.  
 
Figure 2 
The binding activity of the three peptides designed in vacuo was also evaluated using fluorescence 
spectroscopy. This technique allows measuring the binding affinity both in water solution and in water-
methanol mixtures, which are not compatible with the Biacore sensor. Therefore, it allows measuring 
the affinity also in the conditions that are relevant for TDM, and will be exploited for peptides 
specifically designed for this aim. As the peptides are poorly fluorescent, but  they show a good ability 
to quench the fluorescence of CPT-11, we have designed a reversed experiment to obtain the binding 
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affinity. The interaction was therefore studied monitoring the quenching of fluorescence of CPT-11, 
whose concentration was kept constant, upon increasing peptide concentrations. A control experiment 
was carried out on peptide 1, and in this case the recognition event was studied also by monitoring the 
tryptophan emission of the peptide (280/340 nm). Following CPT-11 fluorescence, the excitation and 
emission wavelengths were respectively set at 220 and 430 nm. The experiments were carried out in 
both water and methanol. During the titrations, CPT-11 fluorescence quenching was observed 
increasing the peptide concentration in all cases (Figure 2D and 3A).  
 
                                             a                                                                      b 
Figure 3 
The quenching data were analyzed according to the Stern-Volmer equation (see materials and methods). 
In all cases the quenching constants were well over 10
12
 Lmol
-1
s
-1
, the limit value for collisional 
quenching.  Having thus established that a static quenching phenomenon occurs, we have evaluated the 
dissociation constant of the CPT-11-peptides complexes and the stoichiometry of their formation by a 
Hill analysis of the fluorescence data (see methods).  By this analysis, the peptides 1, 2 and 3 gave a KD 
of 23, 20 and 26 µM in water and 41, 53, 56 µM in methanol respectively (Table 1). The affinity of all 
three peptides in aqueous solution, measured by fluorimetry, is thus consistent with the one measured by 
SPR. On moving from the water environment to methanol, the affinity decreases by a factor 3, bringing 
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the  KD in the medium micromolar range. The Hill number turned out to be 1 in methanol, indicating a 
1:1 binding between peptide and CPT-11, while it is interesting to note an n < 1 in aqueous solution for 
all three peptides. An explanation may be that, in aqueous solution, peptide self-aggregation occurs at 
high concentration, and, in this case, a fraction of binding sites may be hidden  leading to the observed 
apparent negative cooperativity. The decrease of polarity in methanol might reduce the tendency to 
peptide – peptide hydrophobic aggregation thus making available the whole of the binding sites.  
The experimental values of the binding affinity are in good agreement with those obtained by molecular 
dynamics simulation. For each of the three peptides designed in vacuum, we generated trajectories of 
the complex CPT-11-peptide in methanol, and for peptide 1 also in water (see Figure S1 in 
supplementary materials). In all the cases,  the peptide-drug complexes are stable over all simulation 
times with an estimated binding affinity of about -10 kcal/mol (see Figure S2). 
 
Binding affinity of the peptides designed in methanol 
We then considered cyclic peptides specifically designed in methanol, by taking explicitly into account 
the effect of the solvent  interactions by an atomistic description. From this design, we selected two 
peptides, 4 and 5 hereafter (Table 2), whose theoretical binding affinity to CPT-11 in methanol is  -12.5 
kcal/mol. For these peptides, the experimental tests were carried out by fluorescence spectroscopy only, 
since the SPR sensor cannot be used in methanol, and peptides 4 and 5 are not soluble in water. 
The fluorescence quenching experiment showed that a gain in affinity occurs, and the whole titration 
curve of fluorescence emission is shifted down by  one order of magnitude (Figure 3). In order to 
evaluate the dissociation constants of peptides 4 and 5, it was necessary reducing the concentration of 
CPT-11 to 0.5 µM, In this manner, we obtained 4.1 and 6.2 M Kds respectively (Table 2). The binding 
stoichiometry is 1:1 by Hill analysis in both cases. Theoretical and experimental binding affinities in 
methanol for all the five peptides analysed in this work are in fair agreement, as shown in Figure 3 B. 
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This indicates that the theoretical binding affinity, that can be cheaply estimated by molecular dynamics, 
can be safely used to select the best candidate peptides prior to experimental screening. This is at the 
basis of the success of the combined experimental and theoretical procedure described in this work. 
Selectivity of the peptides 
We have also considered the selectivity of the peptides toward CPT-11. Specifically, we carried out 
molecular dynamics (MD) simulation and experiments to analyze the stability of the SN-38-peptide 
complexes, being SN-38 the active metabolite of CPT-11 lacking the carbamate and the piperidyl-
piperidine groups (see Scheme 1). Results in Figure 4 show that peptide 1 is not selective for CPT-11 
since it can also bind SN-38:  the average value of the binding affinity over all the MD trajectory is  
approximately -10 Kcal/mol and -9 Kcal/mol for CPT-11 and SN-38 complex, respectively  (Figure 
4A).  
 
                                           a                                                                      b 
Figure 4 
These results  agree with the fluorescence binding experiment (Figure 4B), that also provide similar 
value for the binding affinity towards these two targets. On the other hand, MD simulations and 
experiments consistently show that peptides 4 and 5 are fully selective toward CPT-11 and unable to 
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bind SN-38. Indeed, we have observed a dissociation of the complexes of SN-38 and peptides 4 and 5 
along the MD trajectory (see Figure S3 in supplementary materials) and a very scarce fluorescence 
quenching in the corresponding experimental titrations (Figure 4B). The selectivity of peptides 4 and 5 
toward CPT-11 further highlight the crucial role of the solvent environment in the stabilization of the 
peptide-drug complex and, thus, the need of design the peptides in an explicit solvent environment. 
Remarkably, peptide 5 is extremely selective toward CPT-11 with a micromolar affinity while not 
binding at all SN-38. We further investigated the molecular basis of this striking difference in binding 
affinity since CPT-11 and SN-38 have rather similar structures (see Scheme 1). We gathered the atoms 
in CPT-11 in groups as shown in the Figure 1, calculating the number of contacts and the minimum 
distance between each group and the peptide. The results of this analysis show that the number of 
contacts between the piperidinyl-piperidine group and the carbamate one are significant. Moreover, the 
oxygen atom of this group remains at about 0.2 nm from the peptide during the whole  MD trajectory 
(see Figure S4 and S5 in Supplementary Materials). Since this group is present only in the CPT-11, this 
could explain the selectivity of the peptide towards this molecule. These results show that the binding 
can be significantly altered, even by removing a single relevant moiety in the target, suggesting that the 
proposed  procedure can design peptides capable of distinguish even targets that are chemically similar. 
We have also carried out a virtual alanine scanning on peptides 4 and 5 in order to identify, from the 
peptide side, the role of each amino acid in selectivity. Ten peptides were generated from peptide 4 and 
from peptide 5 by replacing each amino acid with alanine (the two cysteines were kept in order to 
maintain the disulphide bond), and we have evaluated the change in the VINA binding energy for each 
mutated peptide with respect with the original ones. The results are fully reported in Supplementary 
Materials (Figure S7). In peptide 4, the most relevant difference in binding of CPT-11 and SN38 is 
observed upon replacement of Tyr 3, Gln 4 and Tyr 8, which appear important in driving the selectivity 
of peptide 4 towards CPT-11. In peptide 5, the same role is played by Trp 2, Tyr 3 and Trp 4.  
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4. Conclusion  
In this work we described the experimental validation of short peptides designed in silico as artificial 
receptors for the anticancer drug  (CPT-11). The design procedure is tailored to produce peptides 
capable of recognizing their target in a specific environment, a denaturant in the case of terapeutic drug 
monitoring of CPT-11. Surface plasmon resonance and fluorescence spectroscopy  confirms the 
theoretical predicted binding energies. Moreover, the designed peptides show a high selectivity towards 
CPT-11 respect to its very similar metabolite SN-38.    
To the best of our knowledge, this is the first example of peptides  designed in silico to bind their target  
in an organic solvent (i.e., methanol)  whose activity is then proven experimentally. These results 
further demonstrate the power of our computational and experimental approach, showing evidence that 
short peptides designed in silico can be used as sensing elements for TDM of anticancer drugs. This 
discloses a convenient way to the development of unprecedented biosensors with biomolecules as 
sensing elements working in any organic solvent or at extreme conditions of temperature, pressure and 
pH. 
Acknowledgements 
 We acknowledge the AIRC 5x1000 grant “Application of Advanced Nanotechnology in the 
Development of Innovative Cancer Diagnostics Tools”   
5. References  
 Alnaim, L., 2007.  J. Oncol. Pharm. Pract. 13, 207-221. 
 Del Carlo, M., Capoferri, D., Gladich, I., Guida, F., Forzato, C., Navarini, L., Compagnone, D., Laio, 
A., Berti, F., 2016.   ACS Sensors, 279-286. 
 De Jong, M.E., Huitema, A.D.R.,  Schellens, J.H.M., Rodenhuis, S., Beijnen, J.H. 2005.  Clin. 
Pharmacokinet. 44, 147-173.  
16 
 
 Dey, J., Warner, I. M., 1997. J. Lumin. 71, 105-114. 
 Fassberg, J., Stella, V. J. , 1992.  J. Pharm. Sci. 81, 676 – 684. 
Ferguson, B. S.,  Hoggarth, D.A.,  Maliniak, D.,  Ploense, K.,  White, R. J.,  Woodward, N.,  Hsieh, K., 
Bonham, A. J., Eisenstein, M., Kippin, T. E., Plaxco, K. W., Soh, H. T., 2014. Science Transl. Med. 
5, 213ra165. 
 Gao, B., Yeap, S., Clements, A., Balakrishnar, B., Wong, M., Gurney, H., 2012.  J. Clin. Oncol. 30, 
4017-4025. 
 Gladich, I.,  Rodriguez, A.,  Hong Enriquez, R.P.,  Guida, F.,  Berti, F.,  Laio, A., 2015.  J. Phys. Chem. 
B. 119, 12963-12969. 
 Hess, B., Kutzner, C., Van Der Spoel, D., & Lindahl, E., 2008. Journal of chemical theory and 
computation, 4(3), 435-447. 
Hong Enriquez, R. P., Pavan, S., Benedetti, F., Tossi, A.,  Savoini, A., Berti, F., Laio, A., 2012.   J. 
Chem. Theor. Comput. 8, 1121-1128. 
Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., & Simmerling, C., 2006.  Proteins,  65, 
712-725. 
Ma, Q., Lu, A.Y.H., 2011.  Pharmacol. Rev. 63, 437–459. 
Marangon, E., Posocco, B.,  Mazzega, E., Toffoli, G.,2014.  PLoS ONE 10, e0118194. 
Paci, A., Veal, G., Bardin, C., Levêque, D.,  Widmer, N.,  Beijnen, J., Astier, A., Chatelut, E., 2014.  
Eur. J. Canc. 50, 2010-2019. 
 Trott, O., Olson, A.J., 2010.  Comput. Chem., 31, 455−461.  
Van Erp, N. P., de Wit, D.,  Guchelaar, H.- J.,  Gelderblom, H., Hessing, T. J., Hartigh, J. D., 2014.   J. 
Chromatogr. B. 937, 33-43.  
Walko, C.M., McLeod, H.L., 2014. J. Clin. Oncol. 32, 2581-2586. 
17 
 
Widmer, N., Bardin, C., Chatelut, E., Paci, A., Beijnen, J., Levêque, D., Veal, G., Astier, A., 2014.  Eur. 
J. Canc. 50, 2020-2036. 
 
 
 
 
 
 
 
 
Tables 
Table 1. Binding data for the peptides designed in vacuum. 
§
: The KGGG chain at the amino termini of the peptides 
was added as a spacer to allow immobilization of the peptides on the SPR chip surfaces; 
a
: dissociation constants 
from Hill analysis of the fluorescence quenching data and from (SPR titration); 
b
: Hill number from the fluorescence 
quenching data. 
c
: in water; 
d
: in methanol. 
Peptide Sequence§ Ksv
 
104Lmol-1 
KQ
 
1012Lmol-1s-1 
KD
a 
10-6molL-1 
Nb 
1 KGGGCVHYDMHQYWMC 6.52±0.27c  
5.09±0.12d 
18.5c  
14.2d 
23.4±0.9c (64±2c)  
41.3±0.6d 
0.89c  
1.01d 
2 
 
KGGGCIRNRWNYQYRC 4.50±0.17c 
1.90±0.05d 
11d 
5.1d 
20.2±0.9c (63±3c) 
53±2d 
0.79c 
1.03d 
3 
 
KGGGCWPTGNYYNFGC 3.8±0.08c 
1.7±0.06d 
9.5c 
4.6d 
26±1c (62±2c) 
56±2d 
0.81c 
1.04d 
 
Table 2. Binding data for the peptides designed in methanol. 
a
:  in methanol; 
b
: dissociation constants from Hill 
analysis of the fluorescence quenching data; 
c
: Hill number from the fluorescence quenching data.  
Peptide Sequence Ksv
a 
104Lmol-1 
KQ
a 
1012Lmol-1s-1 
KD
a,b 
10-6molL-1 
Na,c 
4 KGGGCQYQYEIYYYYC 112±8  314 4.1±0.13 0.99 
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5 
 
KGGGCWYWALIIYVRC 217±7  
 
616 6.2±0.11 0.99 
 
 Figure Legends. 
Figure 1. a) the outcome for a typical design alghoritm run, starting from a poly-valine peptide: the 
mean values of Vina score calculated on the design trajectories is given as a function of mutation 
number. The different colors correspond to different efficacious temperatures (see the text). b): complex 
peptide-CPT-11; the complex results to be stable with the CPT-11 (orange) inside the peptide ring. 
Figure 2. Binding of CPT-11 by the peptides designed in vacuum. a-c: SPR sensorgrams and their 
corresponding binding isotherms, obtained immobilizing peptides 1 (blue); 2 (red) and 3 (green)  on the 
sensor chip and increasing CPT-11 concentration. d: Decay of fluorescence emission of 1 µM CPT-11 
at 430 nm upon addition of increasing concentrations of peptides. 
Figure 3. Binding of CPT-11 in methanol. a) Decay of fluorescence emission of 0.5 µM CPT-11 at 430 
nm upon addition of increasing concentrations of peptides in methanol. b) Experimental affinity to CPT-
11 for peptides 1 to 5 vs. the predicted binding energy calculated by molecular dynamics. Theoretical 
and experimental results are truly compatible, and give the same hierarchy of the binding affinity for all 
the considered peptides. The shift between the two groups consisting by peptides 1, 2 and 3 and peptides 
4 and 5 respectively, clearly shows  the algorithm capability of designing environment-specific peptides.  
Figure 4. Selectivity of the peptides towards CPT-11 and SN-38. a) experimental and predicted 
affinities to CPT-11 and SN-38 for peptides 1, 4 and 5. b) fluorescence emission decay of 1 µM CPT-11 
(solid lines) and SN-38 (dotted lines) upon addition of increasing concentrations of peptide 1 (blue), 4 
(pink) and 5 (cyan) in methanol. 
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